comparison of a low molecular weight heparin , kabi 2165 , revealed that it can inhibit fibrin formation in the extracorporeal circulation , that this property is largely reflected in its anti-factor xa activity in plasma , and that a useful and effective dose of kabi 2165 for haemodialysis may be 4,000 anti-factor xa u intravenous bolus + 750 anti-factor xa u/h intravenous maintenance infusion .
C0015982
fibrin
C0032105
plasma